Skip to main content
. 2016 Jan 8;4(2):167–172. doi: 10.3892/br.2016.570

Table III.

Association between the expression of PTPRZ1 and PTN and patient clinicopathological features.

PTN PTPRZ1


Feature No. Mean ± SD P-value Mean ± SD P-value
ER
  Positive 133 137.11±100.33 0.079 364.38±381.03 0.337
  Negative 192 211.52±176.14 464.47±368.00
PR
  Positive 115 147.71±105.44 0.240 401.84±403.62 0.754
  Negative 210 199.39±172.56 435.56±361.02
Her-2
  Positive   78 143.72±47.66 0.316 425.94±366.50 0.980
  Negative 247 193.09±172.78 422.98±379.66
ALN
  Positive 168 195.82±195.50 0.472 394.61±313.51 0.557
  Negative 157 165.46±89.64 455.02±432.42
Tumor size
  <2 cm 132 187.00±109.29 464.22±431.89 0.568
  2–5 cm 157 192.75±194.84 0.486 422.82±360.06
  >5 cm   36 109.92±46.38 278.92±107.37
Menopause
  Yes 138 154.72±95.08 0.278 431.70±194.71 0.893
  No 157 200.80±184.25 417.75±362.76

PTPRZ1, protein tyrosine phosphatase ζ; PTN, pleiotrophin; ER, estrogen receptor, PR, progesterone receptor; ALN, axillary lymph node.